J&J's energy answers are blowing in the wind in Irish collaboration

Janssen's new wind turbine on a grey but relatively still day in Cork, Ireland

J&J says it collaborated with Novartis and GSK to install wind turbines in Cork, Ireland to substantially reduce electricity costs at its local manufacturing plants.

Cork, Ireland is home to a number of big pharma manufacturing sites and amongst them GlaxoSmithKline, Novartis and J&J – through its subsidiaries Janssen Biologics and Depuy Synthes – have teamed up to reduce their environmental impact and cut energy costs by implementing wind turbines to power their processing plants.

Two turbines were officially switched on last week to power both Johnson & Johnson sites, and though the firm “certainly wanted to work towards sustainable energy, the primary driver is the cost of electricity,” Kyran Johnson, General Manager of Janssen’s supply Chain, Ireland, told in-Pharmatechnologist.com.

At Janssen, he told us, the firm expected to see a return on the turbine’s initial cost of around €5m ($6.8m) within six or seven years. “We have a 3.5 megawatt turbine here that will power the entire plant when the wind is blowing and will give us excess that we can feed back into the grid,” he added.

The Depuy medical device site, however, has “a huge volume of processing equipment” and the turbine will only supplement utility costs, he said.

Industry collaboration

For GSK and Novartis, the wind-power will be fed similarly back into their pharma manufacturing plants and the project represents a “very visible” example of how big pharma is working together in Cork.

“It’s a project that’s taken 6 years and not without its challenges,” Johnson told us. “This zone was not designated as a zone for wind turbines so by getting the industry together with IDA [Industrial Development Agency (Ireland)] we’ve said what can we do here?”

By working together, as well as with the authorities and resident groups, the companies were able to create a development plan and leverage significant cost reductions by buying the turbines in bulk.

He added generally within the industry there is a “very high regard for company information that needs to remain confidential,” but projects such as this demonstrate “there is very good sharing of information that doesn’t need to be [kept secret] but can help us influence lobbying government in the EU space, to ensure the industry is well supported.”

Pfizer, who until recently had three manufacturing sites in Cork (Ringaskiddy, Loughbeg and Little Island), was also interested in joining this energy venture. However, Johnson said, at the time the plan was implemented “they decided not to proceed as unfortunately they were going through a downturn and couldn’t get the investment.”

Related News

Ringaskiddy ferry terminal, Cork Harbour,

Pfizer and Irish port authorities working to stop API plant gathering dust

University of Limerick, Ireland. Home to the new manufacturing tech development centre

Techs can help Ireland compete on costs says team behind new hub

Merck's plant near Panaji, Goa.

Why cashews and coconuts are Merck's green energy secret

FTC headquarters in Washington DC

Happy Thanksgiving for GSK with FTC approval of Novartis vaccine biz

Image: iStock

GSK invests €12m in two new Irish API plants

Chancellor George Osborne displaying his red, leathery box. Source Flickr/Chingster23

UK energy cuts good for pharma, API and chem firms says industry group

Pfizer to sell Lipitor API plant

Pfizer Puts Lipitor Site Up For Sale as Patent Expiration Causes Over-Capacity

Pfizer gains 1st ISO 50001 energy accreditation at Ireland plant

GSK: reports of Ireland review are “completely inaccurate”

GSK starts energy reduction programme

Pfizer's plan to sell Little Island API plant falters

BioMarin to buy Pfizer’s Shanbally biologics plant

Related Products

See more related products